<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; Parkinson&#8217;s</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/category/parkinsons/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Stalevo has higher efficacy in Parkinson&#8217;s disease than the current therapy</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2008/05/15/stalevo-has-higher-efficacy-in-parkinsons-disease-than-the-current-therapy/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2008/05/15/stalevo-has-higher-efficacy-in-parkinsons-disease-than-the-current-therapy/#comments</comments>
		<pubDate>Thu, 15 May 2008 17:00:51 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[carbidopa]]></category>
		<category><![CDATA[entacapone]]></category>
		<category><![CDATA[FIRST STEP study]]></category>
		<category><![CDATA[levodopa]]></category>
		<category><![CDATA[Parkinson's disease]]></category>
		<category><![CDATA[Stalevo]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/2008/05/15/stalevo-has-higher-efficacy-in-parkinsons-disease-than-the-current-therapy/</guid>
		<description><![CDATA[A new study in patients with early Parkinson&#8217;s disease demonstrates that Stalevo® (levodopa/carbidopa/entacapone) gives better symptom control and greater improvements in activities of daily living than levodopa/carbidopa, the most widely-used current therapy. The FIRST STEP study, designed to support regulatory filings in 2008 for the use of Stalevo in patients with early Parkinson&#8217;s disease (PD), [...]]]></description>
			<content:encoded><![CDATA[<p><img vspace="5" align="left" width="200" src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2008/05/stalevo.png" hspace="5" alt="Stalevo" height="97" />A new study in patients with early Parkinson&#8217;s disease demonstrates that <a href="http://www.stalevo.com/">Stalevo</a>® (levodopa/carbidopa/entacapone) gives better symptom control and greater improvements in activities of daily living than levodopa/carbidopa, the most widely-used current therapy. The FIRST STEP study, designed to support regulatory filings in 2008 for the use of Stalevo in patients with early Parkinson&#8217;s disease (PD), indicated that the drug may provide greater benefits for patients over and above the levodopa/carbidopa therapy. Stalevo is currently used for certain Parkinson&#8217;s disease patients who experience end-of-dose motor (or movement) fluctuations, known as &#8220;wearing off.&#8221;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2008/05/15/stalevo-has-higher-efficacy-in-parkinsons-disease-than-the-current-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
